Researchers Test Virucidal Activity of WHO Handrub Formulation
A recently modified World Health Organization (WHO) Formulation I was examined as 80 percent and 97 percent solutions against poliovirus type 1, adenovirus type 5 and murine norovirus according to the new European Norm prEN 14476:2011. In a previous study the unmodified WHO Formulation I had failed to demonstrate a sufficient activity against poliovirus type 1 according to the European Norm EN 14476-2007 whereas a sufficient activity was seen with adenovirus and norovirus.
The researchers found that the modified WHO Formulation I demonstrated a virucidal activity against all three test viruses of the European Norm prEN 14476:2011 under clean conditions. This was achieved as 80 percent solution against adeno- and norovirus within 30 seconds and as 97 percent solution against poliovirus within 60 seconds. Testing the unmodified WHO Formulation I against poliovirus type 1 in the 97 percent ass percenty of the European Norm prEN 14476:2011 an identical activity could be demonstrated. When comparing the 80 percent and the 97 percent assay of the European Norm prEN 14476:2011 the modified WHO Formulation I as 80 percent solution was active against adenovirus type 5 within 30 seconds whereas the 97 percent solution failed within 2 minutes exposure time.
The researchers conclude that the technical possibility in the new European Norm prEN 14476:2011 allows testing a ready-to-use disinfectant as 97 percent solution and is responsible for the new virucidal claim of the modified WHO Formulation I. In contrast to the improvements with poliovirus type 1 the activity against adenovirus type 5 decreased when increasing the test concentration from 80 percent to 97 percent. Their research was published in Antimicrobial Resistance and Infection Control.
Steinmann J, Becker B, Bischoff B, Magulski T, Steinmann J and Steinmann E. Virucidal activity of Formulation I of the World Health Organization's alcohol-based handrubs: impact of changes in key ingredient levels and test parameters. Antimicrobial Resistance and Infection Control 2013, 2:34Â doi:10.1186/2047-2994-2-34
The Latest on CLABSIs and CAUTIs: Evidence-Based Approaches for Infection Prevention
February 27th 2025Health care–associated infections like CLABSIs and CAUTIs threaten patient safety. Learn evidence-based strategies, new technologies, and prevention protocols to reduce these infections and improve outcomes.
Resilience and Innovation: The Pivotal Contributions of Black Americans to Health Care and Medicine
February 24th 2025During Black History Month, we honor the resilience and contributions of Black medical professionals in health care. Despite barriers, they have led transformative changes, advocating for equitable access and medical excellence. Recognizing their impact ensures a more inclusive health care future for all.
Glove Usage Guideline: From The Joint Commission, CDC, and World Health Organization
February 17th 2025Proper glove use is crucial in health care settings to prevent infections. Guidelines from TJC, CDC, and WHO stress correct selection, usage, and disposal to minimize health care–associated infections (HAIs) and cross-contamination risks. Infection preventionists (IPs) play a key role in educating staff, enforcing compliance, and improving patient safety through standardized glove practices.
Infection Intel: GermZapp Is the Innovative Hand Hygiene System IPC Needs
February 14th 2025GermZAPP is an affordable hand hygiene system designed to educate, monitor, and encourage adherence in schools, nursing homes, and health care settings, effectively addressing gaps in infection control.
